Targeting survivin and p53 in pediatric acute lymphoblastic leukemia.

Tyner, J W; Jemal, A M; Thayer, M; Druker, B J; Chang, B H

Tyner, J W; Jemal, A M; Thayer, M; Druker, B J; Chang, B H.

Affiliation

Tyner JW; Division of Hematology and Medical Oncology, and OHSU Knight Cancer Institute, OHSU, Portland, OR, USA.

Leukemia ; 26(4): 623-32, 2012 Apr.

Article in En | MEDLINE | ID: mdl-21960246

Subject(s)

Inhibitor of Apoptosis Proteins/antagonists & inhibitors; Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy; Tumor Suppressor Protein p53/antagonists & inhibitors; Apoptosis; Benzamides; Cell Division; Cell Line, Tumor; Fusion Proteins, bcr-abl/antagonists & inhibitors; G2 Phase; Humans; Imatinib Mesylate; Piperazines/therapeutic use; Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics; Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology; Pyrimidines/therapeutic use; Survivin

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Tumor Suppressor Protein p53 / Inhibitor of Apoptosis Proteins / Precursor Cell Lymphoblastic Leukemia-Lymphoma Limits: Humans Language: En Year: 2012 Type: Article

Fulltext

XML

PubMed Links

Search on Google